Silexion Therapeutics (SLXN) Competitors $0.71 -0.04 (-4.93%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. ATHE, OSTX, BRNS, ALGS, PLUR, ALXO, VYNE, GDTC, CLNN, and RVPHShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Alterity Therapeutics (ATHE), OS Therapies (OSTX), Barinthus Biotherapeutics (BRNS), Aligos Therapeutics (ALGS), Pluri (PLUR), ALX Oncology (ALXO), VYNE Therapeutics (VYNE), CytoMed Therapeutics (GDTC), Clene (CLNN), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Alterity Therapeutics OS Therapies Barinthus Biotherapeutics Aligos Therapeutics Pluri ALX Oncology VYNE Therapeutics CytoMed Therapeutics Clene Reviva Pharmaceuticals Silexion Therapeutics (NASDAQ:SLXN) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Does the media favor SLXN or ATHE? In the previous week, Alterity Therapeutics had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for Silexion Therapeutics. Alterity Therapeutics' average media sentiment score of 1.00 beat Silexion Therapeutics' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Silexion Therapeutics Neutral Alterity Therapeutics Positive Do insiders & institutionals believe in SLXN or ATHE? 10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, SLXN or ATHE? Silexion Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Which has preferable earnings and valuation, SLXN or ATHE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A$260KN/AN/AAlterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the MarketBeat Community favor SLXN or ATHE? Alterity Therapeutics received 3 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Silexion Therapeutics an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformSilexion TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesAlterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% Do analysts prefer SLXN or ATHE? Silexion Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 566.67%. Alterity Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 242.86%. Given Silexion Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Silexion Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is SLXN or ATHE more profitable? Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -249.43% Alterity Therapeutics N/A N/A N/A SummaryAlterity Therapeutics beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.52M$2.84B$5.31B$7.34BDividend YieldN/A1.86%5.45%4.34%P/E RatioN/A30.4821.9417.82Price / SalesN/A441.91380.6697.73Price / Cash1.46168.6838.2534.64Price / Book-0.113.466.453.98Net Income$260,000.00-$72.06M$3.22B$247.81M7 Day Performance-11.98%0.33%0.74%0.28%1 Month Performance-34.21%-15.25%-9.66%-7.60%1 Year PerformanceN/A-25.72%11.81%1.49% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.71-4.9%$5.00+601.3%N/A$6.18MN/A0.00N/APositive NewsGap UpATHEAlterity Therapeutics2.5664 of 5 stars$3.21+2.2%$12.00+273.8%+71.6%$28.46MN/A0.0010Short Interest ↓Positive NewsOSTXOS Therapies1.783 of 5 stars$1.31+4.8%$18.00+1,274.0%N/A$28.38MN/A0.00N/AGap UpBRNSBarinthus Biotherapeutics2.8395 of 5 stars$0.70-0.6%$5.17+638.9%-70.9%$28.21M$14.97M-0.47107Short Interest ↓Positive NewsGap UpALGSAligos Therapeutics3.5567 of 5 stars$4.61+13.0%$70.00+1,418.4%-75.0%$28.19M$3.95M-0.3590Positive NewsGap UpPLURPluri0.8422 of 5 stars$3.90+2.1%N/A-25.2%$27.29M$678,000.00-0.70150News CoverageALXOALX Oncology3.0193 of 5 stars$0.50+2.3%$4.14+725.9%-96.5%$26.76MN/A-0.1740VYNEVYNE Therapeutics2.8968 of 5 stars$1.75+12.5%$6.88+292.9%-17.8%$26.62M$501,000.00-2.0330High Trading VolumeGDTCCytoMed Therapeutics2.05 of 5 stars$2.43-2.0%$5.00+105.8%+17.7%$26.58MN/A0.00N/AUpcoming EarningsPositive NewsCLNNClene2.5094 of 5 stars$3.08+1.7%$55.25+1,693.8%-57.0%$26.48M$342,000.00-0.58100Short Interest ↑Gap UpRVPHReviva Pharmaceuticals2.2756 of 5 stars$0.78+15.0%$10.00+1,188.5%-74.1%$25.95MN/A-0.705News Coverage Related Companies and Tools Related Companies Alterity Therapeutics Alternatives OS Therapies Alternatives Barinthus Biotherapeutics Alternatives Aligos Therapeutics Alternatives Pluri Alternatives ALX Oncology Alternatives VYNE Therapeutics Alternatives CytoMed Therapeutics Alternatives Clene Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLXN Stock Free SLXN Stock Alerts